What are the severity grades of chemotherapy-induced nausea and vomiting (CINV)?

Severity Grades of Chemotherapy-Induced Nausea and Vomiting (CINV)

CINV is classified by timing (acute, delayed, anticipatory, breakthrough, refractory) rather than traditional numerical severity grades, though the emetogenic potential of chemotherapy regimens is categorized into 4 risk levels based on the percentage of patients who experience emesis without prophylaxis. 1

Classification by Timing

CINV is most commonly classified by when it occurs relative to chemotherapy administration:

Acute CINV

• Occurs within minutes to several hours after chemotherapy
• Typically resolves within the first 24 hours
• Peak intensity occurs at 5-6 hours post-administration
• More common in women and patients <50 years old 1, 2

Delayed CINV

• Develops >24 hours after chemotherapy administration
• Common with cisplatin, carboplatin, cyclophosphamide, and doxorubicin
• For cisplatin specifically: peaks at 48-72 hours and can persist 6-7 days
• Often more severe than acute nausea and more resistant to treatment 1

Anticipatory CINV

• Occurs before the next chemotherapy treatment
• Represents a conditioned response from prior negative experiences
• Incidence ranges from 18-57%
• Nausea is more common than vomiting
• Younger patients are more susceptible 1, 2

Breakthrough CINV

• Vomiting that occurs despite prophylactic treatment
• Requires "rescue" antiemetic agents 1

Refractory CINV

• Emesis occurring in subsequent treatment cycles when prophylaxis/rescue have failed in earlier cycles 1

Emetogenic Risk Classification

The severity grading system used in clinical practice categorizes chemotherapy regimens by their emetogenic potential (not individual patient symptoms):

Grade 4 (High Emetic Risk)

• ≥90% of patients experience acute emesis without prophylaxis
• Includes cisplatin-based regimens 3, 1, 3

Grade 3 (Moderate Emetic Risk)

• 30-90% of patients experience acute emesis without prophylaxis 3, 1, 3

Grade 1-2 (Low/Minimal Emetic Risk)

• <30% of patients experience acute emesis without prophylaxis 3

CTCAE Severity Grading

When individual patient symptoms are assessed, the Common Terminology Criteria for Adverse Events (CTCAE) provides numerical grades:

• Grade 0: No nausea/vomiting
• Grade 1: Mild symptoms
• Grade 2: Moderate symptoms (≥2 episodes in 24 hours)
• Grade 3: Severe symptoms
• Grade 4: Life-threatening consequences 4, 5, 6

Research shows that grade ≥2 CINV affects approximately 17-18% of patients despite modern antiemetic prophylaxis 6.

Important Clinical Considerations

Risk factors for more severe CINV include:

• Female sex
• Age <50 years
• History of motion sickness or morning sickness during pregnancy
• Low/no alcohol consumption
• Previous CINV episodes
• Anxiety
• Platinum or anthracycline-based chemotherapy 1, 2, 6, 7

Common pitfall: The grading system for chemotherapy emetogenicity (Grades 1-4) is often confused with individual patient symptom severity. The former guides prophylactic antiemetic selection, while CTCAE grades assess actual patient outcomes 1, 4.